National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patient 18 years or older with breast cancer and biopsy-proven malignant involvement of an axillary lymph node
Surgical management will be determined by the surgeon, who will decide if preoperative Iodine (I)-125 seed localization of the positive node is necessary or if they will retrieve the positive node with intraoperative ultrasound guidance. During surgery, the targeted node, its associated biopsy markers, I-125 seed if placed, and optimized twinkling marker will be resected. The position of the marker in the lymph node or proximity to the node will be noted from the surgical and pathology documentation
Surgery will be performed by one of the surgeons in the Division of Breast and Melanoma Surgical Oncology (Doctor \[Dr.\] Judy Boughey, Dr. Amy Degnim, Dr. Tina Hieken, Dr. Jeffrey Johnson, Dr. Mary Mrdutt, Dr. Shon Black)
Patients must be able to understand the study procedures and comply with them for the entire length of the study
No contraception is necessary or required
You may not be if
Patients who are pregnant
Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
Current or past participation within a specified timeframe in another clinical trial, as warranted by the administration of this intervention
Clareo Health | An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial
